Background: Allogeneic hematopoietic cell transplantation (alloHCT) is an established curative treatment for hematological malignancies and other severe blood disorders. However, alloHCT is also known for its significant side effects. Summary: Here we review recent advances in targeted molecular therapy, immunotherapy, infectiology, and diagnostics that have enhanced the tolerability and efficacy of alloHCT, expanding its use to less fit and elderly patients. We analyze developments in conditioning regimens, donor selection, and the management of graft versus host disease (GVHD) and infections and discuss posttransplantation strategies to prevent relapse. Key Message: In a fresh perspective, alloHCT can serve as a platform to enhance the potential of emerging targeted and immune therapies.

1.
Maffini
E
,
Labopin
M
,
Kröger
N
,
Finke
J
,
Stelljes
M
,
Schroeder
T
, et al
.
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the acute leukemia working party of the European society for blood and marrow transplantation (EBMT)
.
Bone Marrow Transplant
.
2024
;
30
(
10
):
024
02275
.
2.
Bazarbachi
A
,
Labopin
M
,
Moukalled
N
,
Kröger
N
,
Rautenberg
C
,
Schetelig
J
, et al
.
Improvements in posttransplant outcomes over two decades in older patients with acute myeloid leukemia in the EBMT ALWP study
.
Clin Cancer Res
.
2024
;
30
(
9
):
1778
87
.
3.
Nagler
A
,
Labopin
M
,
Salmenniemi
U
,
Wu
D
,
Blaise
D
,
Rambaldi
A
, et al
.
Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT
.
Bone Marrow Transplant
.
2024
;
20
(
10
):
024
02379
.
4.
Penack
O
,
Abouqateb
M
,
Peczynski
C
,
Boreland
W
,
Gülbas
Z
,
Gedde-Dahl
T
, et al
.
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
.
Blood Cancer J
.
2024
;
14
(
1
):
45
.
5.
Kyriakou
C
,
Boumendil
A
,
Finel
H
,
Niederwieser
D
,
Andersen
NS
,
Blaise
D
, et al
.
The impact of advanced patient age on mortality after allogeneic hematopoietic cell transplantation for non-hodgkin lymphoma: a retrospective study by the European society for blood and marrow transplantation lymphoma working party
.
Biol Blood Marrow Transplant
.
2019
;
25
(
1
):
86
93
.
6.
McLornan
D
,
Eikema
DJ
,
Czerw
T
,
Kröger
N
,
Koster
L
,
Reinhardt
HC
, et al
.
Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis
.
Bone Marrow Transplant
.
2021
;
56
(
9
):
2160
72
.
7.
Bacigalupo
A
,
Ballen
K
,
Rizzo
D
,
Giralt
S
,
Lazarus
H
,
Ho
V
, et al
.
Defining the intensity of conditioning regimens: working definitions
.
Biol Blood Marrow Transplant
.
2009
;
15
(
12
):
1628
33
.
8.
Gratwohl
A
,
Pasquini
MC
,
Aljurf
M
,
Atsuta
Y
,
Baldomero
H
,
Foeken
L
, et al
.
One million haemopoietic stem-cell transplants: a retrospective observational study
.
Lancet Haematol
.
2015
;
2
(
3
):
e91
100
.
9.
Passweg
JR
,
Baldomero
H
,
Ciceri
F
,
Corbacioglu
S
,
de la Cámara
R
,
Dolstra
H
, et al
.
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
.
Bone Marrow Transplant
.
2023
;
58
(
6
):
647
58
.
10.
Sorror
ML
,
Sandmaier
BM
,
Storer
BE
,
Franke
GN
,
Laport
GG
,
Chauncey
TR
, et al
.
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies
.
JAMA
.
2011
;
306
(
17
):
1874
83
.
11.
Kornblit
B
,
Maloney
DG
,
Storb
R
,
Storek
J
,
Hari
P
,
Vucinic
V
, et al
.
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial
.
Biol Blood Marrow Transplant
.
2013
;
19
(
9
):
1340
7
.
12.
Shouval
R
,
Fein
JA
,
Cho
C
,
Avecilla
ST
,
Ruiz
J
,
Tomas
AA
, et al
.
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT
.
Blood Adv
.
2022
;
6
(
5
):
1525
35
.
13.
Scott
BL
,
Pasquini
MC
,
Logan
BR
,
Wu
J
,
Devine
SM
,
Porter
DL
, et al
.
Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes
.
J Clin Oncol
.
2017
;
35
(
11
):
1154
61
.
14.
Kroger
N
,
Iacobelli
S
,
Franke
GN
,
Platzbecker
U
,
Uddin
R
,
Hübel
K
, et al
.
Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial)
.
J Clin Oncol
.
2017
;
35
(
19
):
2157
64
.
15.
Danylesko
I
,
Shimoni
A
,
Nagler
A
.
Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike
.
Bone Marrow Transplant
.
2012
;
47
(
1
):
5
14
.
16.
Shimoni
A
,
Labopin
M
,
Savani
B
,
Hamladji
RM
,
Beelen
D
,
Mufti
G
, et al
.
Intravenous busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the acute leukemia working party of European society for blood and marrow transplantation
.
Biol Blood Marrow Transplant
.
2018
;
24
(
4
):
751
7
.
17.
Beelen
DW
,
Trenschel
R
,
Stelljes
M
,
Groth
C
,
Masszi
T
,
Reményi
P
, et al
.
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
.
Lancet Haematol
.
2020
;
7
(
1
):
e28
39
.
18.
Shimoni
A
,
Robin
M
,
Iacobelli
S
,
Beelen
D
,
Mufti
GJ
,
Ciceri
F
, et al
.
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT
.
Br J Haematol
.
2021
;
195
(
3
):
417
28
.
19.
Giebel
S
,
Labopin
M
,
Schroeder
T
,
Swoboda
R
,
Maertens
J
,
Bourhis
JH
, et al
.
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
.
Am J Hematol
.
2023
;
98
(
4
):
580
7
.
20.
Hirschbuhl
K
,
Labopin
M
,
Polge
E
,
Blaise
D
,
Bourhis
JH
,
Socié
G
, et al
.
Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT
.
Bone Marrow Transplant
.
2023
;
58
(
8
):
874
80
.
21.
Schmid
C
,
Schleuning
M
,
Ledderose
G
,
Tischer
J
,
Kolb
HJ
.
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome
.
J Clin Oncol
.
2005
;
23
(
24
):
5675
87
.
22.
Schneidawind
D
,
Federmann
B
,
Faul
C
,
Vogel
W
,
Kanz
L
,
Bethge
WA
.
Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia
.
Ann Hematol
.
2013
;
92
(
10
):
1389
95
.
23.
Steckel
NK
,
Groth
C
,
Mikesch
JH
,
Trenschel
R
,
Ottinger
H
,
Kordelas
L
, et al
.
High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia
.
Br J Haematol
.
2018
;
180
(
6
):
840
53
.
24.
Owattanapanich
W
,
Ungprasert
P
,
Wais
V
,
Kungwankiattichai
S
,
Bunjes
D
,
Kuchenbauer
F
.
FLAMSA-RIC for stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndromes: a systematic review and meta-analysis
.
J Clin Med
.
2019
;
8
(
9
):
1437
.
25.
Craddock
C
,
Jackson
A
,
Loke
J
,
Siddique
S
,
Hodgkinson
A
,
Mason
J
, et al
.
Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia
.
J Clin Oncol
.
2021
;
39
(
7
):
768
78
.
26.
Stelljes
M
,
Middeke
JM
,
Bug
G
,
Wagner-Drouet
EM
,
Müller
LP
,
Schmid
C
, et al
.
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
.
Lancet Haematol
.
2024
;
11
(
5
):
e324
35
.
27.
Schulz
F
,
Jäger
P
,
Tischer
J
,
Fraccaroli
A
,
Bug
G
,
Hausmann
A
, et al
.
Smart conditioning with venetoclax-enhanced sequential FLAMSA + RIC in patients with high-risk myeloid malignancies
.
Cancers
.
2024
;
16
(
3
):
532
.
28.
Sloas
C
,
Gill
S
,
Klichinsky
M
.
Engineered CAR-macrophages as adoptive immunotherapies for solid tumors
.
Front Immunol
.
2021
;
12
:
783305
.
29.
Pan
K
,
Farrukh
H
,
Chittepu
VCSR
,
Xu
H
,
Pan
CX
,
Zhu
Z
.
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
.
J Exp Clin Cancer Res
.
2022
;
41
(
1
):
119
.
30.
Liu
E
,
Marin
D
,
Banerjee
P
,
Macapinlac
HA
,
Thompson
P
,
Basar
R
, et al
.
Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
.
N Engl J Med
.
2020
;
382
(
6
):
545
53
.
31.
Hu
Y
,
Zhang
M
,
Yang
T
,
Mo
Z
,
Wei
G
,
Jing
R
, et al
.
Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis
.
N Engl J Med
.
2024
;
390
(
16
):
1467
80
.
32.
Han
L
,
Zhao
R
,
Yang
J
,
Zu
Y
,
Liu
Y
,
Zhou
J
, et al
.
Case Report: successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph+ B cell acute lymphoblastic leukemia
.
Front Immunol
.
2022
;
13
.
33.
Patterson
MT
,
Khan
SM
,
Nunes
NS
,
Fletcher
RE
,
Bian
J
,
Hadjis
AD
, et al
.
Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects
.
Blood
.
2023
;
141
(
6
):
659
72
.
34.
Saha
A
,
Hyzy
S
,
Lamothe
T
,
Hammond
K
,
Clark
N
,
Lanieri
L
, et al
.
A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice
.
Blood
.
2022
;
139
(
11
):
1743
59
.
35.
Czechowicz
A
,
Palchaudhuri
R
,
Scheck
A
,
Hu
Y
,
Hoggatt
J
,
Saez
B
, et al
.
Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation
.
Nat Commun
.
2019
;
10
(
1
):
617
.
36.
Breda
L
,
Papp
TE
,
Triebwasser
MP
,
Yadegari
A
,
Fedorky
MT
,
Tanaka
N
, et al
.
In vivo hematopoietic stem cell modification by mRNA delivery
.
Science
.
2023
;
381
(
6656
):
436
43
.
37.
Gragert
L
,
Eapen
M
,
Williams
E
,
Freeman
J
,
Spellman
S
,
Baitty
R
, et al
.
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry
.
N Engl J Med
.
2014
;
371
(
4
):
339
48
.
38.
Buck
K
,
Wadsworth
K
,
Setterholm
M
,
Maiers
M
,
Confer
D
,
Hartzman
R
, et al
.
High-resolution match rate of 7/8 and 9/10 or better for the Be the match unrelated donor registry
.
Biol Blood Marrow Transplant
.
2016
;
22
(
4
):
759
63
.
39.
Kollman
C
,
Spellman
SR
,
Zhang
MJ
,
Hassebroek
A
,
Anasetti
C
,
Antin
JH
, et al
.
The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy
.
Blood
.
2016
;
127
(
2
):
260
7
.
40.
Fleischhauer
K
,
Beelen
DW
.
HLA mismatching as a strategy to reduce relapse after alternative donor transplantation
.
Semin Hematol
.
2016
;
53
(
2
):
57
64
.
41.
Fleischhauer
K
,
Shaw
BE
.
HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities
.
Blood
.
2017
;
130
(
9
):
1089
96
.
42.
Ruggeri
A
,
De Wreede
LC
,
Müller
CR
,
Crivello
P
,
Bonneville
EF
,
Petersdorf
EW
, et al
.
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
.
Haematologica
.
2023
;
108
(
2
):
645
52
.
43.
Petersdorf
EW
,
Stevenson
P
,
Bengtsson
M
,
De Santis
D
,
Dubois
V
,
Gooley
T
, et al
.
HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation
.
Blood
.
2020
;
136
(
3
):
362
9
.
44.
Fuchs
EJ
,
McCurdy
SR
,
Solomon
SR
,
Wang
T
,
Herr
MM
,
Modi
D
, et al
.
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide
.
Blood
.
2022
;
139
(
10
):
1452
68
.
45.
Petersdorf
EW
,
Gooley
T
,
Volt
F
,
Kenzey
C
,
Madrigal
A
,
McKallor
C
, et al
.
Use of the HLA-B leader to optimize cord blood transplantation
.
Haematologica
.
2021
;
106
(
12
):
3107
14
.
46.
Kröger
N
,
Zabelina
T
,
de Wreede
L
,
Berger
J
,
Alchalby
H
,
van Biezen
A
, et al
.
Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings
.
Leukemia
.
2013
;
27
(
3
):
604
9
.
47.
Guru Murthy
GS
,
Kim
S
,
Hu
ZH
,
Estrada-Merly
N
,
Abid
MB
,
Aljurf
M
, et al
.
Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors
.
JAMA Oncol
.
2022
;
8
(
3
):
404
11
.
48.
Canaani
J
,
Savani
BN
,
Labopin
M
,
Huang
XJ
,
Ciceri
F
,
Arcese
W
, et al
.
Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation
.
Am J Hematol
.
2018
;
93
(
2
):
246
53
.
49.
Ljungman
P
,
Brand
R
,
Hoek
J
,
de la Camara
R
,
Cordonnier
C
,
Einsele
H
, et al
.
Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation
.
Clin Infect Dis
.
2014
;
59
(
4
):
473
81
.
50.
Kalra
A
,
Williamson
T
,
Daly
A
,
Savoie
ML
,
Stewart
DA
,
Khan
F
, et al
.
Impact of donor and recipient cytomegalovirus serostatus on outcomes of antithymocyte globulin-conditioned hematopoietic cell transplantation
.
Biol Blood Marrow Transplant
.
2016
;
22
(
9
):
1654
63
.
51.
Shaw
BE
,
Mayor
NP
,
Szydlo
RM
,
Bultitude
WP
,
Anthias
C
,
Kirkland
K
, et al
.
Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants
.
Bone Marrow Transplant
.
2017
;
52
(
5
):
717
25
.
52.
Shaw
BE
,
Logan
BR
,
Spellman
SR
,
Marsh
SGE
,
Robinson
J
,
Pidala
J
, et al
.
Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most
.
Biol Blood Marrow Transplant
.
2018
;
24
(
5
):
1049
56
.
53.
Wachsmuth
LP
,
Patterson
MT
,
Eckhaus
MA
,
Venzon
DJ
,
Gress
RE
,
Kanakry
CG
.
Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression
.
J Clin Investig
.
2019
;
129
(
6
):
2357
73
.
54.
Fletcher
RE
,
Nunes
NS
,
Patterson
MT
,
Vinod
N
,
Khan
SM
,
Mendu
SK
, et al
.
Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs
.
Blood Adv
.
2023
;
7
(
7
):
1117
29
.
55.
Reisner
Y
,
Kapoor
N
,
Kirkpatrick
D
,
Pollack
MS
,
Dupont
B
,
Good
RA
, et al
.
Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells
.
Lancet
.
1981
;
2
(
8242
):
327
31
.
56.
Bethge
WA
,
Eyrich
M
,
Mielke
S
,
Meisel
R
,
Niederwieser
D
,
Schlegel
PG
, et al
.
Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients
.
Bone Marrow Transplant
.
2022
;
57
(
3
):
423
30
.
57.
Schumm
M
,
Lang
P
,
Taylor
G
,
Kuçi
S
,
Klingebiel
T
,
Bühring
HJ
, et al
.
Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device
.
J Hematother
.
1999
;
8
(
2
):
209
18
.
58.
Federmann
B
,
Bornhauser
M
,
Meisner
C
,
Kordelas
L
,
Beelen
DW
,
Stuhler
G
, et al
.
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study
.
Haematologica
.
2012
;
97
(
10
):
1523
31
.
59.
Schumm
M
,
Lang
P
,
Bethge
W
,
Faul
C
,
Feuchtinger
T
,
Pfeiffer
M
, et al
.
Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device
.
Cytotherapy
.
2013
;
15
(
10
):
1253
8
.
60.
Bleakley
M
,
Sehgal
A
,
Seropian
S
,
Biernacki
MA
,
Krakow
EF
,
Dahlberg
A
, et al
.
Naive T-cell depletion to prevent chronic graft-versus-host disease
.
J Clin Oncol
.
2022
;
40
(
11
):
1174
85
.
61.
Bolanos-Meade
J
,
Hamadani
M
,
Wu
J
,
Al Malki
MM
,
Martens
MJ
,
Runaas
L
, et al
.
Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis
.
N Engl J Med
.
2023
;
388
(
25
):
2338
48
.
62.
Battipaglia
G
,
Labopin
M
,
Blaise
D
,
Diez-Martin
JL
,
Bazarbachi
A
,
Vitek
A
, et al
.
Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone in acute myelogenous leukemia: a retrospective study on behalf of the acute leukemia working party of the European society for blood and marrow transplantation
.
Transplant Cell Ther
.
2022
;
28
(
9
):
587 e1
7
.
63.
El-Cheikh
J
,
Devillier
R
,
Dulery
R
,
Massoud
R
,
Al Chami
F
,
Ghaoui
N
, et al
.
Impact of adding antithymocyte globulin to posttransplantation cyclophosphamide in haploidentical stem-cell transplantation
.
Clin Lymphoma Myeloma Leuk
.
2020
;
20
(
9
):
617
23
.
64.
Storb
R
,
Deeg
HJ
,
Farewell
V
,
Doney
K
,
Appelbaum
F
,
Beatty
P
, et al
.
Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease
.
Blood
.
1986
;
68
(
1
):
119
25
.
65.
Ratanatharathorn
V
,
Nash
RA
,
Przepiorka
D
,
Devine
SM
,
Klein
JL
,
Weisdorf
D
, et al
.
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation
.
Blood
.
1998
;
92
(
7
):
2303
14
.
66.
Nash
RA
,
Antin
JH
,
Karanes
C
,
Fay
JW
,
Avalos
BR
,
Yeager
AM
, et al
.
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
.
Blood
.
2000
;
96
(
6
):
2062
8
.
67.
Bolanos-Meade
J
,
Reshef
R
,
Fraser
R
,
Fei
M
,
Abhyankar
S
,
Al-Kadhimi
Z
, et al
.
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
.
Lancet Haematol
.
2019
;
6
(
3
):
e132
43
.
68.
Bacigalupo
A
,
Oneto
R
,
Lamparelli
T
,
Gualandi
F
,
Bregante
S
,
Raiola
AM
, et al
.
Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG)
.
Bone Marrow Transplant
.
2001
;
28
(
12
):
1093
6
.
69.
Walker
I
,
Panzarella
T
,
Couban
S
,
Couture
F
,
Devins
G
,
Elemary
M
, et al
.
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial
.
Lancet Oncol
.
2016
;
17
(
2
):
164
73
.
70.
Finke
J
,
Schmoor
C
,
Bethge
WA
,
Ottinger
H
,
Stelljes
M
,
Volin
L
, et al
.
Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial
.
Lancet Haematol
.
2017
;
4
(
6
):
e293
301
.
71.
Soiffer
RJ
,
Kim
HT
,
McGuirk
J
,
Horwitz
ME
,
Johnston
L
,
Patnaik
MM
, et al
.
Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation
.
J Clin Oncol
.
2017
;
35
(
36
):
4003
11
.
72.
Kroger
N
,
Solano
C
,
Wolschke
C
,
Bandini
G
,
Patriarca
F
,
Pini
M
, et al
.
Antilymphocyte globulin for prevention of chronic graft-versus-host disease
.
N Engl J Med
.
2016
;
374
(
1
):
43
53
.
73.
Chang
YJ
,
Wu
DP
,
Lai
YR
,
Liu
QF
,
Sun
YQ
,
Hu
J
, et al
.
Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study
.
J Clin Oncol
.
2020
;
38
(
29
):
3367
76
.
74.
Cho
BS
,
Min
GJ
,
Park
SS
,
Yoon
SY
,
Park
S
,
Jeon
YW
, et al
.
Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor
.
Am J Hematol
.
2021
;
96
(
11
):
1441
9
.
75.
Bonifazi
F
,
Solano
C
,
Wolschke
C
,
Sessa
M
,
Patriarca
F
,
Zallio
F
, et al
.
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study
.
Lancet Haematol
.
2019
;
6
(
2
):
e89
99
.
76.
Binkert
L
,
Medinger
M
,
Halter
JP
,
Heim
D
,
Gerull
S
,
Holbro
A
, et al
.
Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation
.
Bone Marrow Transplant
.
2015
;
50
(
10
):
1331
6
.
77.
Hoeg
RT
,
Moroz
A
,
Gandhi
A
,
Muffly
L
,
Shiraz
P
,
Oliai
C
, et al
.
Orca-T results in high gvhd-free and relapse-free survival following myeloablative conditioning for hematological malignancies: results of a single center phase 2 and a multicenter phase 1b study
.
Blood
.
2021
;
138
(
Suppl 1
):
98
.
78.
MacMillan
ML
,
Hippen
KL
,
McKenna
DH
,
Kadidlo
D
,
Sumstad
D
,
DeFor
TE
, et al
.
First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings
.
Blood Adv
.
2021
;
5
(
5
):
1425
36
.
79.
Rashidi
A
,
Ebadi
M
,
Rehman
TU
,
Elhusseini
H
,
Kazadi
D
,
Halaweish
H
, et al
.
Potential of fecal microbiota transplantation to prevent acute GVHD: analysis from a phase II trial
.
Clin Cancer Res
.
2023
;
29
(
23
):
4920
9
.
80.
DeFilipp
Z
,
Damania
AV
,
Kim
HT
,
Chang
CC
,
El-Jawahri
A
,
McAfee
SL
, et al
.
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract
.
Blood Adv
.
2024
;
8
(
9
):
2074
84
.
81.
Kean
LS
,
Burns
LJ
,
Kou
TD
,
Kapikian
R
,
Lozenski
K
,
Langston
A
, et al
.
Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation
.
Blood
.
2024
;
144
(
17
):
1834
45
.
82.
Chen
Y-B
,
Saad
A
,
Farhan
SY
,
Lekakis
LJ
,
Schiller
GJ
,
Yared
JA
, et al
.
RGI-2001 infusion for prevention of acute gvhd after allogeneic hematopoietic cell transplantation
.
Blood
.
2022
;
140
(
Suppl 1
):
1877
8
.
83.
Zhang
X
,
Zhao
X
,
Chen
S
,
Hao
M
,
Zhang
L
,
Gong
M
, et al
.
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients
.
Bone Marrow Transplant
.
2024
;
59
(
7
):
997
1005
.
84.
Abboud
R
,
Schroeder
MA
,
Rettig
MP
,
Gao
F
,
Ritchey
JK
,
Abboud
CN
, et al
.
Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome with T-cell replete peripheral blood haploidentical transplantation
.
Blood
.
2023
;
142
(
Suppl 1
):
651
.
85.
Holtan
SG
.
Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus
.
Blood
.
2023
;
142
(
Supplement 1
):
4925
.
86.
Waller
EK
,
Horwitz
M
,
Anand
S
,
Tey
SK
,
Berger
M
,
Preiss
R
, et al
.
MODULAATE (Part 1): an open-label, dose-finding phase 2 evaluation of alpha-1 antitrypsin for the prevention of graft-versus-host disease in patients receiving hematopoietic cell transplantation
.
Transplant Cell Ther
.
2024
;
30
(
2Suppl
):
S261
.
87.
Sandmaier
BM
,
Kornblit
B
,
Storer
BE
,
Olesen
G
,
Maris
MB
,
Langston
AA
, et al
.
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial
.
Lancet Haematol
.
2019
;
6
(
8
):
e409
18
.
88.
Zeiser
R
,
Polverelli
N
,
Ram
R
,
Hashmi
SK
,
Chakraverty
R
,
Middeke
JM
, et al
.
Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease
.
N Engl J Med
.
2021
;
385
(
3
):
228
38
.
89.
Zeiser
R
,
von Bubnoff
N
,
Butler
J
,
Mohty
M
,
Niederwieser
D
,
Or
R
, et al
.
Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease
.
N Engl J Med
.
2020
;
382
(
19
):
1800
10
.
90.
Abedin
S
,
Rashid
N
,
Schroeder
M
,
Romee
R
,
Nauffal
M
,
Alhaj Moustafa
M
, et al
.
Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease: a real-world outcomes analysis
.
Br J Haematol
.
2021
;
195
(
3
):
429
32
.
91.
Magenau
JM
,
Goldstein
SC
,
Peltier
D
,
Soiffer
RJ
,
Braun
T
,
Pawarode
A
, et al
.
α(1)-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease
.
Blood
.
2018
;
131
(
12
):
1372
9
.
92.
Abedin
S
,
Hamadani
M
,
Holtan
SG
,
Schiller
GJ
,
Gallogly
M
,
Waller
EK
, et al
.
Neihulizumab (ALTB-168) in patients with steroid-refractory acute graft-versus-host-disease (SR-aGVHD) or treatment-refractory acute graft-versus-host-disease (TR-aGVHD)
.
Blood
.
2022
;
140
(
Suppl 1
):
10495
7
.
93.
Dimitriadou
V
,
Chabot-Roy
G
,
Audiger
C
,
Banu
I
,
Delisle
JS
,
Lesage
S
.
P3.05: apraglutide decreases severity of intestinal damage from acute gastrointestinal graft versus host disease (GI-GvHD) following allogeneic transplantation without impacting engraftment
.
Transplantation
.
2022
;
106
(
9S
):
S520
1
.
94.
Chen
YB
,
Mohty
M
,
Zeiser
R
,
Teshima
T
,
Jamy
O
,
Maertens
J
, et al
.
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
.
Nat Med
.
2024
;
30
(
8
):
2277
87
.
95.
Holtan
SG
,
Hoeschen
A
,
Cao
Q
,
Ustun
C
,
Betts
BC
,
Jurdi
NE
, et al
.
Phase II, open-label clinical trial of urinary-derived human chorionic gonadotropin/epidermal growth factor for life-threatening acute graft-versus-host disease
.
Transplant Cell Ther
.
2023
;
29
(
8
):
509.e1
8
.
96.
Pidala
J
,
Walton
K
,
Elmariah
H
,
Kim
J
,
Mishra
A
,
Bejanyan
N
, et al
.
Pacritinib combined with sirolimus and low-dose tacrolimus for GVHD prevention after allogeneic hematopoietic cell transplantation: preclinical and phase I trial results
.
Clin Cancer Res
.
2021
;
27
(
10
):
2712
22
.
97.
Ponce
DM
,
Alousi
AM
,
Nakamura
R
,
Slingerland
J
,
Calafiore
M
,
Sandhu
KS
, et al
.
A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract
.
Blood
.
2023
;
141
(
12
):
1389
401
.
98.
Rodríguez-Gil
A
,
Escamilla-Gómez
V
,
Nufer
M
,
Andújar-Sánchez
F
,
Lopes-Ramos
T
,
Bejarano-García
JA
, et al
.
Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib
.
Sci Rep
.
2022
;
12
(
1
):
8348
.
99.
Li
Y-R
,
Zeng
S
,
Dunn
ZS
,
Zhou
Y
,
Li
Z
,
Yu
J
, et al
.
Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers
.
iScience
.
2022
;
25
(
9
):
104859
.
100.
Kadri
N
,
Amu
S
,
Iacobaeus
E
,
Boberg
E
,
Le Blanc
K
.
Current perspectives on mesenchymal stromal cell therapy for graft versus host disease
.
Cell Mol Immunol
.
2023
;
20
(
6
):
613
25
.
101.
Akahoshi
Y
,
Spyrou
N
,
Weber
D
,
Aguayo-Hiraldo
P
,
Ayuk
F
,
Chanswangphuwana
C
, et al
.
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
.
Blood
.
2024
;
144
(
9
):
1010
21
.
102.
Miklos
D
,
Cutler
CS
,
Arora
M
,
Waller
EK
,
Jagasia
M
,
Pusic
I
, et al
.
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
.
Blood
.
2017
;
130
(
21
):
2243
50
.
103.
Cutler
C
,
Lee
SJ
,
Arai
S
,
Rotta
M
,
Zoghi
B
,
Lazaryan
A
, et al
.
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
.
Blood
.
2021
;
138
(
22
):
2278
89
.
104.
Wolff
D
,
Cutler
C
,
Lee
SJ
,
Pusic
I
,
Bittencourt
H
,
White
J
, et al
.
Axatilimab in recurrent or refractory chronic graft-versus-host disease
.
N Engl J Med
.
2024
;
391
(
11
):
1002
14
.
105.
Zeiser
R
.
Novel approaches to the treatment of chronic graft-versus-host disease
.
J Clin Oncol
.
2023
;
41
(
10
):
1820
4
.
106.
Bader
P
,
Kreyenberg
H
,
von Stackelberg
A
,
Eckert
C
,
Salzmann-Manrique
E
,
Meisel
R
, et al
.
Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial
.
J Clin Oncol
.
2015
;
33
(
11
):
1275
84
.
107.
Balduzzi
A
,
Di Maio
L
,
Silvestri
D
,
Songia
S
,
Bonanomi
S
,
Rovelli
A
, et al
.
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention
.
Br J Haematol
.
2014
;
164
(
3
):
396
408
.
108.
Ossenkoppele
G
,
Schuurhuis
GJ
.
MRD in AML: does it already guide therapy decision-making
.
Hematol Am Soc Hematol Educ Program
.
2016
;
2016
(
1
):
356
65
.
109.
Dohner
H
.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
.
Blood
.
2022
;
140
(
12
):
1345
77
.
110.
Heuser
M
,
Freeman
SD
,
Ossenkoppele
GJ
,
Buccisano
F
,
Hourigan
CS
,
Ngai
LL
, et al
.
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
.
Blood
.
2021
;
138
(
26
):
2753
67
.
111.
Conter
V
,
Bartram
CR
,
Valsecchi
MG
,
Schrauder
A
,
Panzer-Grümayer
R
,
Möricke
A
, et al
.
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
.
Blood
.
2010
;
115
(
16
):
3206
14
.
112.
Gokbuget
N
,
Kneba
M
,
Raff
T
,
Trautmann
H
,
Bartram
CR
,
Arnold
R
, et al
.
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
.
Blood
.
2012
;
120
(
9
):
1868
76
.
113.
Bassan
R
,
Spinelli
O
.
Minimal residual disease monitoring in adult ALL to determine therapy
.
Curr Hematol Malig Rep
.
2015
;
10
(
2
):
86
95
.
114.
Balsat
M
,
Renneville
A
,
Thomas
X
,
de Botton
S
,
Caillot
D
,
Marceau
A
, et al
.
Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute leukemia French association group
.
J Clin Oncol
.
2017
;
35
(
2
):
185
93
.
115.
Jongen-Lavrencic
M
,
Grob
T
,
Hanekamp
D
,
Kavelaars
FG
,
Al Hinai
A
,
Zeilemaker
A
, et al
.
Molecular minimal residual disease in acute myeloid leukemia
.
N Engl J Med
.
2018
;
378
(
13
):
1189
99
.
116.
Buckley
SA
,
Wood
BL
,
Othus
M
,
Hourigan
CS
,
Ustun
C
,
Linden
MA
, et al
.
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
.
Haematologica
.
2017
;
102
(
5
):
865
73
.
117.
Walter
RB
,
Gyurkocza
B
,
Storer
BE
,
Godwin
CD
,
Pagel
JM
,
Buckley
SA
, et al
.
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
.
Leukemia
.
2015
;
29
(
1
):
137
44
.
118.
Araki
D
,
Wood
BL
,
Othus
M
,
Radich
JP
,
Halpern
AB
,
Zhou
Y
, et al
.
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission
.
J Clin Oncol
.
2016
;
34
(
4
):
329
36
.
119.
Terwijn
M
,
Zeijlemaker
W
,
Kelder
A
,
Rutten
AP
,
Snel
AN
,
Scholten
WJ
, et al
.
Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia
.
PLoS One
.
2014
;
9
(
9
):
e107587
.
120.
Zeijlemaker
W
,
Kelder
A
,
Oussoren-Brockhoff
YJM
,
Scholten
WJ
,
Snel
AN
,
Veldhuizen
D
, et al
.
A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia
.
Leukemia
.
2016
;
30
(
2
):
439
46
.
121.
Waterhouse
M
,
Pennisi
S
,
Pfeifer
D
,
Scherer
F
,
Zeiser
R
,
Duyster
J
, et al
.
Monitoring of measurable residual disease using circulating DNA after allogeneic hematopoietic cell transplantation
.
Cancers
.
2022
;
14
(
14
):
3307
.
122.
Kolb
HJ
,
Mittermüller
J
,
Clemm
C
,
Holler
E
,
Ledderose
G
,
Brehm
G
, et al
.
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
.
Blood
.
1990
;
76
(
12
):
2462
5
.
123.
Flutter
B
,
Edwards
N
,
Fallah-Arani
F
,
Henderson
S
,
Chai
JG
,
Sivakumaran
S
, et al
.
Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation
.
J Clin Investig
.
2010
;
120
(
11
):
3855
68
.
124.
Saha
A
,
O’Connor
RS
,
Thangavelu
G
,
Lovitch
SB
,
Dandamudi
DB
,
Wilson
CB
, et al
.
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality
.
J Clin Investig
.
2016
;
126
(
7
):
2642
60
.
125.
Davids
MS
,
Kim
HT
,
Bachireddy
P
,
Costello
C
,
Liguori
R
,
Savell
A
, et al
.
Ipilimumab for patients with relapse after allogeneic transplantation
.
N Engl J Med
.
2016
;
375
(
2
):
143
53
.
126.
Herbaux
C
,
Gauthier
J
,
Brice
P
,
Drumez
E
,
Ysebaert
L
,
Doyen
H
, et al
.
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
.
Blood
.
2017
;
129
(
18
):
2471
8
.
127.
Davids
MS
,
Kim
HT
,
Costello
C
,
Herrera
AF
,
Locke
FL
,
Maegawa
RO
, et al
.
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation
.
Blood
.
2020
;
135
(
24
):
2182
91
.
128.
Henden
AS
,
Varelias
A
,
Leach
J
,
Sturgeon
E
,
Avery
J
,
Kelly
J
, et al
.
Pegylated interferon-2α invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation
.
Blood Adv
.
2019
;
3
(
20
):
3013
9
.
129.
Bailey
C
,
Wei
Y
,
Yan
J
,
Huang
D
,
Zhang
P
,
Qi
C
, et al
.
Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease
.
Cell Rep Med
.
2023
;
4
(
11
):
101236
.
130.
Ciceri
F
,
Bonini
C
,
Stanghellini
MTL
,
Bondanza
A
,
Traversari
C
,
Salomoni
M
, et al
.
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study
.
Lancet Oncol
.
2009
;
10
(
5
):
489
500
.
131.
Song
Y
,
Zhu
Y
,
Hu
B
,
Liu
Y
,
Lin
D
,
Jin
Z
, et al
.
Donor γδT cells promote GVL effect and mitigate aGVHD in allogeneic hematopoietic stem cell transplantation
.
Front Immunol
.
2020
;
11
:
558143
.
132.
Schlegel
P
,
Lang
AM
,
Matela
M
,
Horrer
A
,
Schilling
A
,
Jöchner
A
, et al
.
Ex vivo expansion of autologous, donor-derived NK-γδT-and cytokine induced killer (CIK) cells post haploidentical hematopoietic stem cell transplantation results in increased antitumor activity
.
Bone Marrow Transplant
.
2019
;
54
(
Suppl 2
):
727
32
.
133.
Phely
L
,
Hensen
L
,
Faul
C
,
Ruff
CA
,
Schneider
D
,
Bethge
WA
, et al
.
Allogeneic CD19/CD22 CAR T-cell therapy for B-cell acute lymphoblastic leukemia
.
JAMA Oncol
.
2024
;
10
(
6
):
821
4
.
134.
Mathew
NR
,
Baumgartner
F
,
Braun
L
,
O’Sullivan
D
,
Thomas
S
,
Waterhouse
M
, et al
.
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
.
Nat Med
.
2018
;
24
(
3
):
282
91
.
135.
Burchert
A
,
Bug
G
,
Fritz
LV
,
Finke
J
,
Stelljes
M
,
Röllig
C
, et al
.
Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3–internal tandem duplication mutation (SORMAIN)
.
J Clin Oncol
.
2020
;
38
(
26
):
2993
3002
.
136.
Xuan
L
,
Wang
Y
,
Huang
F
,
Fan
Z
,
Xu
Y
,
Sun
J
, et al
.
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
.
Lancet Oncol
.
2020
;
21
(
9
):
1201
12
.
137.
Gagelmann
N
,
Wolschke
C
,
Klyuchnikov
E
,
Christopeit
M
,
Ayuk
F
,
Kröger
N
.
TKI maintenance after stem-cell transplantation for FLT3-ITD positive acute myeloid leukemia: a systematic review and meta-analysis
.
Front Immunol
.
2021
;
12
:
630429
.
138.
Metzelder
SK
,
Schroeder
T
,
Finck
A
,
Scholl
S
,
Fey
M
,
Götze
K
, et al
.
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
.
Leukemia
.
2012
;
26
(
11
):
2353
9
.
139.
Fathi
AT
,
Kim
HT
,
Soiffer
RJ
,
Levis
MJ
,
Li
S
,
Kim
AS
, et al
.
Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1-mutated acute myeloid leukemia
.
Clin Cancer Res
.
2023
;
29
(
11
):
2034
42
.
140.
Kantarjian
HM
,
DeAngelo
DJ
,
Stelljes
M
,
Martinelli
G
,
Liedtke
M
,
Stock
W
, et al
.
Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia
.
N Engl J Med
.
2016
;
375
(
8
):
740
53
.
141.
Ueda
M
,
de Lima
M
,
Caimi
P
,
Tomlinson
B
,
Little
J
,
Creger
R
, et al
.
Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant
.
Bone Marrow Transplant
.
2016
;
51
(
9
):
1253
5
.
142.
Gaballa
MR
,
Banerjee
P
,
Milton
DR
,
Jiang
X
,
Ganesh
C
,
Khazal
S
, et al
.
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia
.
Blood
.
2022
;
139
(
12
):
1908
19
.
143.
Beer
SA
,
Bethge
W
,
Faul
C
,
Lengerke
C
,
Vogel
W
.
Case report: sequential inotuzumab, blinatumomab, and chemotherapy with concurrent donor lymphocyte infusions induce complete remission in relapsed pre-B acute lymphoblastic leukemia
.
EJHaem
.
2024
;
5
(
3
):
620
3
.
144.
Konopleva
M
,
Pollyea
DA
,
Potluri
J
,
Chyla
B
,
Hogdal
L
,
Busman
T
, et al
.
Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia
.
Cancer Discov
.
2016
;
6
(
10
):
1106
17
.
145.
DiNardo
CD
,
Pratz
K
,
Pullarkat
V
,
Jonas
BA
,
Arellano
M
,
Becker
PS
, et al
.
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
.
Blood
.
2019
;
133
(
1
):
7
17
.
146.
Pollyea
DA
,
Stevens
BM
,
Jones
CL
,
Winters
A
,
Pei
S
,
Minhajuddin
M
, et al
.
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
.
Nat Med
.
2018
;
24
(
12
):
1859
66
.
147.
Cluzeau
T
,
Sebert
M
,
Loschi
M
,
Ades
L
,
Thepot
S
,
Carre
M
, et al
.
Phase I/II clinical trial evaluating azacitidine + venetoclax + donor lymphocyte infusion in post-transplant relapse myelodysplastic syndromes and acute myeloid leukemia: preliminary results of ventograft, a GFM study
.
Blood
.
2023
;
142
(
Suppl 1
):
3246
.
148.
Murdock
HM
,
Ho
VT
,
Garcia
JS
.
Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect
.
Front Immunol
.
2024
;
15
(
1359113
):
1359113
.
149.
Chen
YB
,
Li
S
,
Lane
AA
,
Connolly
C
,
Del Rio
C
,
Valles
B
, et al
.
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia
.
Biol Blood Marrow Transplant
.
2014
;
20
(
12
):
2042
8
.
150.
Schlenk
RF
,
Weber
D
,
Fiedler
W
,
Salih
HR
,
Wulf
G
,
Salwender
H
, et al
.
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
.
Blood
.
2019
;
133
(
8
):
840
51
.
151.
Sandmaier
BM
,
Khaled
S
,
Oran
B
,
Gammon
G
,
Trone
D
,
Frankfurt
O
.
Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant
.
Am J Hematol
.
2018
;
93
(
2
):
222
31
.
152.
Fathi
AT
,
Kim
HT
,
Soiffer
RJ
,
Levis
MJ
,
Li
S
,
Kim
AS
, et al
.
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
.
Blood Adv
.
2022
;
6
(
22
):
5857
65
.
153.
Garcia
JS
,
Kim
HT
,
Murdock
HM
,
Cutler
CS
,
Brock
J
,
Gooptu
M
, et al
.
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
.
Blood Adv
.
2021
;
5
(
24
):
5536
45
.
154.
Mishra
A
,
Tamari
R
,
DeZern
AE
,
Byrne
MT
,
Gooptu
M
,
Chen
YB
, et al
.
Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes
.
J Clin Oncol
.
2022
;
40
(
34
):
3985
93
.
155.
Bug
G
,
Burchert
A
,
Wagner
EM
,
Kröger
N
,
Berg
T
,
Güller
S
, et al
.
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
.
Leukemia
.
2017
;
31
(
11
):
2523
5
.
156.
Cooperrider
JH
,
Fulton
N
,
Artz
AS
,
Larson
RA
,
Stock
W
,
Kosuri
S
, et al
.
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome
.
Bone Marrow Transplant
.
2020
;
55
(
11
):
2204
6
.
157.
Bhatt
VR
,
Wichman
C
,
Bouska
AC
,
Maness
L
,
Al-Kadhimi
ZS
,
Iqbal
J
, et al
.
Novel first-in-class drug ONC201 as a post-transplant maintenance for AML and MDS: a phase I trial in progress
.
Blood
.
2022
;
140
(
Suppl 1
):
12918
9
.
158.
Maertens
JA
,
Rahav
G
,
Lee
DG
,
Ponce-de-León
A
,
Ramírez Sánchez
IC
,
Klimko
N
, et al
.
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
.
Lancet
.
2021
;
397
(
10273
):
499
509
.
159.
Tissot
F
,
Agrawal
S
,
Pagano
L
,
Petrikkos
G
,
Groll
AH
,
Skiada
A
, et al
.
ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients
.
Haematologica
.
2017
;
102
(
3
):
433
44
.
160.
Cornely
OA
,
Arikan-Akdagli
S
,
Dannaoui
E
,
Groll
AH
,
Lagrou
K
,
Chakrabarti
A
, et al
.
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013
.
Clin Microbiol Infect
.
2014
;
20
(
Suppl 3
):
5
26
.
161.
White
PL
,
Barnes
RA
,
Springer
J
,
Klingspor
L
,
Cuenca-Estrella
M
,
Morton
CO
, et al
.
Clinical performance of Aspergillus PCR for testing serum and plasma: a study by the European Aspergillus PCR initiative
.
J Clin Microbiol
.
2015
;
53
(
9
):
2832
7
.
162.
Marty
FM
,
Ljungman
P
,
Chemaly
RF
,
Maertens
J
,
Dadwal
SS
,
Duarte
RF
, et al
.
Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation
.
N Engl J Med
.
2017
;
377
(
25
):
2433
44
.
163.
Ljungman
P
,
de la Camara
R
,
Robin
C
,
Crocchiolo
R
,
Einsele
H
,
Hill
JA
, et al
.
Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)
.
Lancet Infect Dis
.
2019
;
19
(
8
):
e260
72
.
164.
Avery
RK
,
Alain
S
,
Alexander
BD
,
Blumberg
EA
,
Chemaly
RF
,
Cordonnier
C
, et al
.
Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial
.
Clin Infect Dis
.
2022
;
75
(
4
):
690
701
.
165.
Neuenhahn
M
,
Albrecht
J
,
Odendahl
M
,
Schlott
F
,
Dössinger
G
,
Schiemann
M
, et al
.
Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT
.
Leukemia
.
2017
;
31
(
10
):
2161
71
.
166.
Obermaier
B
,
Braun
C
,
Hensen
L
,
Ahmad
O
,
Faul
C
,
Lang
P
, et al
.
Adenovirus- and cytomegalovirus-specific adoptive T-cell therapy in the context of hematologic cell transplant or HIV infection: a single-center experience
.
Transpl Infect Dis
.
2024
;
26
(
4
):
e14296
.
167.
Feuchtinger
T
,
Lücke
J
,
Hamprecht
K
,
Richard
C
,
Handgretinger
R
,
Schumm
M
, et al
.
Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation
.
Br J Haematol
.
2005
;
128
(
4
):
503
9
.
168.
Muffly
LS
,
Kocherginsky
M
,
Stock
W
,
Chu
Q
,
Bishop
MR
,
Godley
LA
, et al
.
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients
.
Haematologica
.
2014
;
99
(
8
):
1373
9
.
169.
Hegde
A
,
Murthy
HS
.
Frailty: the missing piece of the pre-hematopoietic cell transplantation assessment
.
Bone Marrow Transplant
.
2018
;
53
(
1
):
3
10
.
170.
Weller
JF
,
Lengerke
C
,
Finke
J
,
Schetelig
J
,
Platzbecker
U
,
Einsele
H
, et al
.
Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study
.
Haematologica
.
2024
;
109
(
2
):
431
43
.
171.
Aldoss
I
,
Shan
H
,
Yang
D
,
Clark
MC
,
Al Malki
M
,
Aribi
A
, et al
.
Consolidation with first and second allogeneic transplants in adults with relapsed/refractory B-ALL following response to CD19CAR T cell therapy
.
Transplant Cell Ther
.
2024
;
30
(
8
):
788 e1
9
.
172.
Fielding
AK
,
Richards
SM
,
Chopra
R
,
Lazarus
HM
,
Litzow
MR
,
Buck
G
, et al
.
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
.
Blood
.
2007
;
109
(
3
):
944
50
.
173.
Li
Y
,
Li
Y
,
Zhang
M
,
Zhao
H
,
Zhu
M
,
Huang
H
, et al
.
Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation
.
Eur J Haematol
.
2024
;
112
(
1
):
94
101
.
174.
Htut
M
,
Dhakal
B
,
Cohen
AD
,
Martin
T
,
Berdeja
JG
,
Usmani
SZ
, et al
.
Ciltacabtagene autoleucel in patients with prior allogeneic stem cell transplant in the CARTITUDE-1 study
.
Clin Lymphoma Myeloma Leuk
.
2023
;
23
(
12
):
882
8
.
175.
Jiang
Y
,
Feng
D
,
Zhu
J
,
Wei
D
,
Zhao
C
,
Liu
H
, et al
.
Case report: preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation
.
Front Immunol
.
2024
;
15
:
1381308
.
176.
Cordas Dos Santos
DM
,
Tix
T
,
Shouval
R
,
Gafter-Gvili
A
,
Alberge
JB
,
Cliff
ERS
, et al
.
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
.
Nat Med
.
2024
;
30
(
9
):
2667
78
.
You do not currently have access to this content.